CoChat

A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy

Open access

The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index.

Abstract

p53 and INK4a/ARF mutations promote tumorigenesis and drug resistance, in part, by disabling apoptosis. We show that primary murine lymphomas also respond to chemotherapy by engaging a senescence program controlled by p53 and p16(INK4a). Hence, tumors with p53 or INK4a/ARF mutations-but not those lacking ARF alone-respond poorly to cyclophosphamide therapy in vivo. Moreover, tumors harboring a Bcl2-mediated apoptotic block undergo a drug-induced cytostasis involving the accumulation of p53, p16(INK4a), and senescence markers, and typically acquire p53 or INK4a mutations upon progression to a terminal stage. Finally, mice bearing tumors capable of drug-induced senescence have a much better prognosis following chemotherapy than those harboring tumors with senescence defects. Therefore, cellular senescence contributes to treatment outcome in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0092-8674(02)00734-1

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 1,050

Metadata

Authors
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W.
Affiliations
  • Cold Spring Harbor Laboratory (US)
  • AntiCancer (United States) (US)
Corresponding author
Lowe, Scott W.
Venue
Cell
Publisher
Elsevier BV
Published
2002-05
Volume
109
Issue
3
Pages
335-346
ISSN
0092-8674 (ISSN-L)
OpenAlex
W1990161819
Cited by
1,050
References
48
Citations by year
2026: 15 · 2025: 33 · 2024: 25 · 2023: 37 · 2022: 32 · 2021: 34 · 2020: 37 · 2019: 42 · 2018: 34 · 2017: 34 · 2016: 51 · 2015: 40 · 2014: 42 · 2013: 56 · 2012: 50
FWCI
37.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
Funders
  • National Institutes of Health (1r43ca089779-01)
  • National Cancer Institute (CA-87497, P01CA087497, CA89779, P30CA008748)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
cellular senescence, p53, p16INK4a, ARF, lymphoma, cyclophosphamide, chemotherapy response, drug resistance, Bcl-2, apoptosis, tumor progression, prognosis
MeSH terms
Animals, Cell Survival, Cyclophosphamide, Mice, Mutant Strains, Mutation, Prognosis, Proto-Oncogene Proteins, Tumor Cells, Cultured, Biomarkers, Tumor Suppressor Protein p53, Lymphoma, B-Cell, Cellular Senescence, Apoptosis, Mice, Knockout, Antineoplastic Agents, Alkylating, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Cyclin-Dependent Kinase Inhibitor p16, Tumor Suppressor Protein p14ARF, Ubiquitin-Protein Ligases, Proto-Oncogene Proteins c-cbl, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy. https://app.cochat.ai/papers/10.1016/s0092-8674(02)00734-1
The paper
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002). A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy. Cell. https://doi.org/10.1016/s0092-8674(02)00734-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.